Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies
JH Chen, MK Pezhouh, GY Lauwers… - The American journal of …, 2017 - journals.lww.com
Programmed cell death protein 1 (PD-1) blocking agents are novel immunotherapeutics
used for treatment of advanced-stage malignancies. They have shown promise in the
treatment of several malignancies, with greater efficacy and better tolerability than cytotoxic
T-lymphocyte antigen 4 (CTLA-4) blocking agents. However, as with anti-CTLA-4 agents,
clinically significant colitis remains an important complication. Although there is growing
awareness of the histopathologic features of anti-CTLA-4 therapy, there is little information …
used for treatment of advanced-stage malignancies. They have shown promise in the
treatment of several malignancies, with greater efficacy and better tolerability than cytotoxic
T-lymphocyte antigen 4 (CTLA-4) blocking agents. However, as with anti-CTLA-4 agents,
clinically significant colitis remains an important complication. Although there is growing
awareness of the histopathologic features of anti-CTLA-4 therapy, there is little information …